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Abstract
Background: Tiludronate and clodronate are FDA-approved bisphosphonate drug therapies for navicular disease in
horses. Although clinical studies have determined their ability to reduce lameness associated with skeletal disorders
in horses, data regarding the effect on bone structure and remodeling is lacking. Additionally, due to off-label use
of these drugs in young performance horses, effects on bone in young horses need to be investigated. Therefore,
the purpose of this randomized, experimental pilot study was to determine the effect of tiludronate and clodronate
on normal bone cells, structure and remodeling after 60 days in clinically normal, young horses. Additionally, the
effect of clodronate on bone healing 60 days after an induced defect was investigated.
Results: All horses tolerated surgery well, with no post-surgery lameness and all acquired biopsies being adequate
for analyses. Overall, tiludronate and clodronate did not significantly alter any bone structure or remodeling parameters,
as evaluated by microCT and dynamic histomorphometry. Tiludronate did not extensively impact bone formation or
resorption parameters as evaluated by static histomorphometry. Similarly, clodronate did not affect bone formation or
resorption after 60 days. Sixty days post-defect, healing was minimally affected by clodronate.
Conclusions: Tiludronate and clodronate do not appear to significantly impact bone tissue on a structural or cellular
level using standard dose and administration schedules.
Keywords: Horse, Bone, Bisphosphonate, Clodronate, Tiludronate, Micro-computed tomography, Histomorphometry,
Biopsy
Background
Tiludronate disodium (Tildren, Ceva Animal Health
LLC, Lenexa, KS, USA) and Clodronate disodium
(Osphos, Dechra, Ltd., Staffordshire, UK) are bisphos-
phonate drugs that are licensed for use in horses to re-
duce lameness associated with navicular disease [1, 2].
Tiludronate and clodronate are non-nitrogen containing
bisphosphonates that reduce osteoclastic bone resorp-
tion by causing osteoclast apoptosis [3]. Tiludronate has
been used to treat conditions associated with bone re-
modeling, such as navicular disease [4, 5] and tarsal
osteoarthritis [6]; however, none of these studies have
evaluated the effect of tiludronate on bony tissue and
have only evaluated the effects on lameness outcomes.
Clodronate is similar to tiludronate in drug properties
and has been shown to have an analgesic effect by acting
on glutamate and/or adenosine triphosphate-related pain
transmission pathways [7]. Tiludronate has not been
shown to have such analgesic properties. The Freedom
of Information (FOI) Summary for both clodronate and
tiludronate report on the clinical outcome in a group of
horses diagnosed with navicular disease. Treated horses
displayed clinical improvements in their degree of lame-
ness; however, neither FOI Summary study discerns
whether the reduction in lameness associated with either
drug is due to the effect on bone remodeling, analgesic
potential (specifically in regards to clodronate), or other
mechanisms.
The FOI summary for clodronate describes the effects
on bone mineral content, cortical bone strength and bone
marrow evaluation evaluated by radiographic photometry,
mechanical testing and histopathology, respectively, in
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normal horses. No difference were reported in these pa-
rameters between treated and saline controls at 6 months
[1]. However, the methods regarding how bone density
data were obtained were not stated, and given the poor
sensitivity of radiographs to determine bone density [8], it
is uncertain whether there was or was not a true effect on
bone in this cohort. The FOI summary for tiludronate
evaluated the 3rd metatarsal and metacarpal, 3rd carpal
and navicular bone in 30 horses for pathological bone le-
sions using histopathology and found no abnormal bone
tissue or resorption sites [2]. However, given the little de-
tails provided on how these assessments were performed,
these outcomes may not be sensitive or reliable enough to
determine bony effects.
Despite its known effect on bone remodeling rates in
other species, the effect of clodronate on bone healing,
especially in the horse, is unclear. In animal models, clo-
dronate has been found to not alter endochondral bone
formation within the fracture callus or epiphyseal plate
of rats [9, 10]. However, reports regarding effects of clo-
dronate are conflicting, including no changes in bone
mineral density in a callus [11], 30% increase in bone
mineral density [10], increased calcium content within
the callus [12], and decreased healing callus strength
[13]. Recently, it has been shown that osteoclasts are a
necessary component of efficient endochondral ossifica-
tion during fracture repair in mice [14]; therefore, it is
possible that clodronate may impair normal bone heal-
ing in horses, which calls for careful consideration when
used in a clinical setting.
The gold standard for bone analyses are histomorpho-
metry [15] and micro-computed tomography (microCT)
[16], both of which require bone biopsies. The tuber
coxae has been reported to be the easiest site for bone
biopsy acquisition in the horse [17, 18] and is a region
that was found to have consistently higher levels of tilu-
dronate in comparison to other bones [19]. A study pub-
lished by the authors has shown the tuber coxae as a site
to obtain reliable bony samples in a non-terminal equine
model that are consistent in size and of adequate quality
to evaluate trabecular bone using both histomorphome-
try and microCT [17].
Therefore, the purpose of this study is to evaluate the
effect of clodronate and tiludronate on bone morph-
ology, bony cells and bone remodeling in young horses.
Additionally, the effect of clodronate on bone healing
after an induced defect was also investigated. These eval-
uations were performed by obtaining bone biopsies of
the tuber coxae using an established technique [17], and
evaluated through histomorphometry and microCT. To
evaluate bone healing, subsequent biopsies were taken
from the initial biopsy site, which served as a novel bone
defect model in the horse. We hypothesized that tiludro-
nate and clodronate would reduce osteoclast number
and function, resulting in increased bone volume and in-
creased bone apposition when compared to baseline bi-
opsies and untreated horses, as well as increased bone
formation after injury in clodronate treated horses.
Methods
Study design
The experimental protocol was approved by the Louisi-
ana State University Institutional Animal Care and Use
Committee (IACUC). Nineteen Thoroughbred horses,
between 2 and 5 years of age were obtained via donation
to the Louisiana State University Equine Health Studies
Program Herd. Medical history of the horses was un-
known at the time of donation; however, all horses
underwent at least a two-week isolation and washout
period following donation prior to enrollment in the
current study. Horses were randomly assigned, via a coin
flip, to either a treatment (TIL: n = 5, CLO: n = 5) or
control group (SAL: n = 9) (Table 1). Two separate stud-
ies were completed, individually assessing the impact of
TIL or CLO respectively, resulting in slightly different
study designs (i.e., inclusion of the re-biopsy outlined
below in the CLO study). No significant differences in
control groups were found, therefore they were
Table 1 Age (years), treatment and biopsies collected from
study subjects. Day 0 biopsies were baseline biopsies collected
on Day 0, Day 60 biopsies were collected from the contralateral
side 60 days post-treatment, and Day 60R biopsies were
collected from the ipsilateral side 60 days post- defect and
post-treatment. Summary Information for Study Subjects
ID Age (yrs) Treatment Biopsies collected
1 5 Saline Day 0, Day 60, Day 60R
2 4 Saline Day 0, Day 60, Day 60R
3 3 Saline Day 0, Day 60, Day 60R
4 4 Saline Day 0, Day 60, Day 60R
5 3 Saline Day 0, Day 60
6 5 Saline Day 0, Day 60
7 2 Saline Day 0, Day 60
8 3 Saline Day 0, Day 60
9 4 Saline Day 0, Day 60
10 5 Tiludronate Day 0, Day 60
11 3 Tiludronate Day 0, Day 60
12 3 Tiludronate Day 0, Day 60
13 5 Tiludronate Day 0, Day 60
14 2 Tiludronate Day 0, Day 60
15 5 Clodronate Day 0, Day 60, Day 60R
16 4 Clodronate Day 0, Day 60, Day 60R
17 4 Clodronate Day 0, Day 60, Day 60R
18 3 Clodronate Day 0, Day 60, Day 60R
19 3 Clodronate Day 0, Day 60, Day 60R
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combined into a single control group. Because this is a
novel pilot study, sample sizes were calculated based on
available data for tiludronate in another species using
the same endpoints (microCT & histomorphometry)
[20], which found that n = 5 was sufficient to identify
bony changes. Additionally, horses served as their own
control, as bilateral biopsies were taken from each ani-
mal, thereby eliminating the need for additional horses.
The surgeon, who was not involved in subsequent ana-
lyses, was not masked to treatment groups.
Bone biopsies were taken from each subject; a baseline
biopsy at Day 0, a contralateral biopsy 60 days post-
treatment (Day 60) (Fig. 1). Additionally, a re-biopsy of
the initial biopsy site was taken from clodronate-treated
horses and a subset of control horses 60 days post-
treatment (Day 60R). This 60-day time frame was deter-
mined based on data in previous studies that showed a
positive effect of tiludronate administration on various
skeletal disorders in horses 60 days post initiation of
treatment [5, 6, 21]. The right or left tuber coxae was
randomly selected, via coin flip, for the first biopsy (out-
lined below in “Surgical Procedure”). Immediately fol-
lowing the initial biopsy surgery (Day 0), each horse was
either administered 1 L of 0.9% saline IV (tiludronate
control), 1 mg/kg of tiludronate dissolved in 1 L of 0.9%
saline IV, or 1.8 mg/kg of clodronate IM (dose was di-
vided into three injection locations) or a similar volume
of 0.9% saline IM (clodronate control). Saline and tilu-
dronate were infused intravenously over 90 min using an
IV fluid pump. The horses stood in the stocks during
drug administration and were monitored for signs of
colic. Sixty days later, the contralateral tuber coxae was
biopsied in the same manner. Additionally, clodronate
treated horses (n = 5) and half of the control horses
(n = 4) were evaluated for bone healing after a defect.
Therefore, an additional biopsy (60R Day) was obtained
from these horses only by taking a re-biopsy of the
initial biopsy site, 60 days post- defect (i.e., the original
biopsy collection). Prior to the 60 day biopsies, oxytetra-
cycline (Vetrimycin 100, VetOne, Boise, ID, USA) was
administered at Day 47 and Day 57 as a fluorochrome
label. Biopsies were evaluated with microCT and histo-
morphometry for changes in bone morphology and
remodeling rates, as outlined below under “Biopsy hand-
ling and imaging”.
Study subjects
Thoroughbred horses, as outlined above under “Study
Design”, were included if they were free from outward
musculoskeletal disease as assessed by a boarded veter-
inary surgeon during a physical exam, and were between
two to five years of age. A coin flip was used to ran-
domly assign horses to a treatment group (e.g., treated
or saline) and only the surgeon (CFM) knew group as-
signments until subsequent statistical analyses on data
collected were ready to be performed. Throughout the
study, they were housed in individual stalls following the
biopsies and then turned out in groups in pastures. They
were fed free choice hay and water, with grain being pro-
vided twice daily.
Surgical Procedure & Treatment
Horses were restrained in stocks and sedated with IV
xylazine (Xylamed, Bimeda, Cambridge, ON, Canada)
(0.35 to 0.5 mg/kg). The surgical method has been previ-
ously published in detail [17]. In short, the biopsy site
was centered on the proximal palpable protuberance of
the tuber coxae. A rectangular region (approximately
10 cm X 10 cm) was clipped around the tuber coxae and
then aseptically prepared. Lidocaine (Lidocaine 2%,
VetOne, Boise, ID, USA) was injected subcutaneously
4 cm proximal and distal to the palpable tuber coxae,
and then deeply to the periosteum of the tuber coxae.
The horse was further sedated with detomidine (Dormo-
sedan, Zoetis, Kalamazoo, MI, USA) (3 to 5 mg IV) and
butorphanol tartrate (Torbugesic, Fort Dodge, New
York, NY, USA) (3 to 5 mg IV) prior to making the skin
incision [17].
A vertical incision was made over the tuber coxae, and
dissected to expose the cranial, caudal, proximal and
axial margins. The lateral periosteum was incised using
a scalpel blade, and then an oscillating saw was used to
transect the proximal portion of the tuber coxae. In
order to limit thermal damage, the saw blade was con-
tinuously lavaged with saline. The surgery site was
lavaged, and then the subcutaneous tissue and skin were
sutured separately. An aluminium based bandage spray
(Aluspray, Neogen Corporation, Lexington, KY, USA)
was applied to the surgery site and a lidocaine patch
(Lidocaine Patch 5%, Qualitest, Huntsville, AL, USA)
was then applied over the incision [17].
Fig. 1 Study design. Study design time line, outlining biopsy collection
and treatment administration
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Following the initial biopsy (Day 0 Biopsy), horses
were stalled for at least 24 h and monitored every 2 h
over the first 24-h period using a visual pain score [22].
After 24 h, horses were returned to their respective
pastures and checked daily for signs of lameness or in-
cisional complications until suture removal at 14 days
post biopsy. At Day 47 and 57 post-biopsy, the horses
were treated with 25 mg/kg of oxytetracycline adminis-
tered slowly IV [17, 23]. Sixty days after the initial bi-
opsy, the contralateral tuber coxae was biopsied (Day
60 biopsy), and the ipsilateral tuber coxae was re-
biopsies in a subset of horses (Day 60R biopsy) using
the same surgical methods as described above. Careful
consideration was made when placing the oscillating
saw for the re-biopsy (60R) to ensure an adequately-
sized biopsy of the tuber coxae was obtained without
cutting into the pelvis. In addition to aforementioned
post-surgical care for the initial biopsy, after surgery to
obtain the 60R biopsy, horses were administered flu-
nixin meglumine (Prevail, Bimeda, Cambridge, ON,
Canada) (1.1 mg/kg IV) for an additional analgesic. Sur-
gical aftercare was then identical following this repeat
biopsy to the care following the initial biopsy from the
post-surgery period to 14 days later when the sutures
were removed.
MicroCT
Following biopsy, tuber coxae samples were dissected
free from tissue and fixed in 10% non-buffered forma-
lin for 7 days, then transferred to and stored in 70%
ethanol at 20 °C. Samples were placed in holders with
70% ethanol for scanning by microCT (Scanco model
40, Scanco Medical AG, Basserdorf, Switzerland). Bi-
opsies were scanned at 55 kV, 0.3-s integration time,
with a 30 μm voxel size in plane and a 30 μm slice
thickness. MicroCT data for two Day 0 biopsies from
clodronate-treated samples were not obtained because
motion artifact occurred during the scan, and this
issue was not identified until the samples had been
decalcified for histology. The region of interest was de-
termined for trabecular bone. The proper threshold for
image segmentation was tested, with the same thresh-
old being used throughout the experiment to ensure
consistency and accuracy in measurements between
samples. Trabecular bone was evaluated for bone vol-
ume (BV), total volume (TV), BV/TV, tissue mineral
density, trabecular number (TbN), trabecular thickness
(TbTh), trabecular separation (TbSp), connectivity
density (ConnD), and structural model index (SMI)
based on established procedures and nomenclature
[24]. A detailed list of these parameters, including defi-
nitions, has been previously published by Bouxsein, et
al. (Table 2 within reference [24]).
Histology
Following microCT evaluation, biopsies were prepared
for histology. Day 0 and Day 60R biopsies were prepared
for decalcified histology, and Day 60 biopsies were pre-
pared for plastic-embedded undecalcified histology using
standard methods so visualization of fluorochrome labels
was possible. Due to differences in preparation tech-
niques between decalcified and undecalcified histology,
and size of slides used for each, histological preparation
of both sets of biopsies differed slightly. However, care
was taken to ensure sections from each biopsy were
taken in the same location and plane of section, regard-
less of preparation method. Day 0 and Day 60R biopsies
were decalcified with 10% ethylenediaminetetraacetic
acid (EDTA) and prepared for routine paraffin embed-
ding. In order to fit on glass histological slides, Day 0 bi-
opsies were split in half and embedded separately. This
resulted in 6–8, 4 μm thick sections per biopsy that were
stained with hematoxylin and eosin (H&E). Day 60 biop-
sies were prepared intact for undecalcified histology and
two, 45–60 μm thick sections were produced. The first
was stained with Stevenel’s Blue and Van Gieson’s picro-
fuchsin for evaluation by static histomorphometry, and
the second section was left unstained for evaluation by
dynamic histomorphometry. Although histological slides
for Day 0 and Day 60 biopsies were prepared differently
for ease of handling, all bony features were easily dis-
cernable and comparable [25, 26] in both sets of slides,
as outlined in Fig. 2.
All bone histomorphometry evaluations were per-
formed by an individual (HAR) using histomorphometry
software (Osteomeasure© Bone Histomorphometry Sys-
tem, Osteometrics, Inc., Decatur, GA, USA) following
standard procedures and nomenclature [26]. Measure-
ments were taken per standardized and published proto-
cols [26]. Static histomorphometry parameters included
direct measurements of: tissue area (TA), BV, marrow
volume (MaV), bone perimeter (BPm), osteoblast perim-
eter (ObPm), bone surface (BS), eroded surface (ES),
reversal surface (RevS), osteoblast number (NOb), osteo-
blast surface (ObS), osteoclast number (NOc), osteoclast
surface (OcS). Indirect measurements included: TbN,
TbTh, TbSp, and the aforementioned direct measure-
ments standardized to respective areas and volumes. Os-
teoblasts and osteoclasts were identified by their unique
morphologic characteristics [27, 28]. A detailed list of
these parameters, including definitions, has been previ-
ously published by Dempster, et al. (Tables 3 & 5 within
reference [26]). However, due to normal variation in bi-
opsy sizes, only parameters normalized to areas and
volumes were evaluated statistically. Dynamic histomor-
phometry included mineralizing surface per bone surface
(MS/BS), mineral apposition rate (MAR) and the bone
formation rate per total volume (BFR/TV). A detailed
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list of these parameters, including definitions, has been
previously published by Dempster, et al (Tables 4 & 5
within reference [26]).
Statistics
Data were tested for normality using the Shapiro-Wilk
test, and depending on normality, either parametric or
non-parametric analyses were used. If data were para-
metric, microCT and histomorphometry data were ana-
lyzed using one-way ANOVA analysis to determine the
effect of treatment within Day 0 or Day 60 biopsy. If sig-
nificance was found, a Tukey post-hoc analysis was
evaluated. If data were nonparametric, microCT and his-
tomorphometry data was analyzed using an Independent
Samples Mann-Whitney U Test, comparing TIL or CLO
to SAL. A Student’s t-test was performed to determine
the effect of clodronate on bone healing parameters,
comparing CLO to SAL within Day 60R biopsy. Add-
itionally, a related-sample test was used to evaluate
changes from Day 0 biopsy to Day 60R biopsy, within
the SAL or CLO horses. Statistical analyses were per-
formed using commercially-available software (SPSS,
version 22, IBM Corporation, Armonk, NY, USA), and
p-values of < 0.05 were considered significant. Due to
the aforementioned issues with obtaining microCT data
from two Day 0 biopsies, all data from those horses were
excluded from dependent analyses.
Results
Surgical technique
All surgeries were successful in obtaining adequately
sized bone biopsies during each attempt, with only one
horse experiencing incisional dehiscence. However, this
complication resolved with minimal medical interven-
tion. No horses displayed any rear limb lameness or rat-
able discomfort at any time over the duration of this
study. Day 0, Day 60 and Day 60R biopsies had a mean
(± SD) volume of 1632 ± 785, 1347 ± 622 and 1080 ±
646 mm3, respectively.
Bone morphology
Select results are outlined in Table 2. When comparing
microCT data between three treatment (saline, clodro-
nate, tiludronate) groups within Day 0 biopsy or within
Day 60 biopsy, there was no significant effect of treat-
ment on any of the 19 bone morphology parameters as
evaluated by microCT. Similarly, there were no signifi-
cant changes in bone morphology parameters between
Day 0 and Day 60 biopsies within treated horses as eval-
uated by microCT. However, when evaluating bone
morphology using static histomorphometry, TIL-treated
horses had a significant increase in BS/TV after 60 days
when compared to control (p = 0.02).
Cellular structure
Select results are outlined in Table 2. There were minor
differences when evaluating bone formation parameters.
When comparing TIL-treated horses to control horses
within the Day 60 biopsy, there was a significant decrease
in NOb/TA (p = 0.004) and NOb/BPm (p = 0.003), and a
significant increase in NOb/ObPm (p < 0.000). When
making the similar comparison within Day 60 biopsy,
CLO-treated horses did not have significantly different
bone formation parameters when compared to control.
Overall, TIL significantly altered three of four normalized
bone formation parameters, while CLO did not have an
effect.
There were also minor differences when evaluating
bone resorption parameters. When comparing TIL-
treated horses to control horses, there was a significant
increase in ES/BS (p = 0.001) and RevS/BS (p = 0.001)
after 60 days. There were no significant changes in bone
resorption parameters within CLO-treated horses com-
pared to control horses after 60 days. Overall, TIL
Fig. 2 Overview of bony features for different histological preparations. Representative histologic sections of (a) decalcified Day 0 biopsy and (b)
un-decalcified Day 60 biopsy, highlighting similar trabecular bone features. Abbreviations: B, bone; BM, bone marrow. Black arrows = osteoblasts;
white arrows = osteocytes
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significantly altered two of six normalized bone resorp-
tion parameters, while CLO did not have an effect.
Bone remodeling kinetics
Select results are outlined in Table 2. After 60 days,
there was no effect of either treatment on any of the 14
bone remodeling parameters evaluated via dynamic
histomorphometry.
Bone healing
When comparing CLO-treated horses to control horses
within the Day 60R biopsy, there was no significant ef-
fect on any of the 19 bone morphology parameters, as
evaluated by microCT (Table 2). When comparing
changes from baseline biopsy to Day 60R biopsy within
CLO-treated and SAL-treated horses, there were no sig-
nificant differences in any of the 19 bone morphology
parameters evaluated via microCT. Comparing CLO-
treated horses to control horses within the Day 60R bi-
opsy using histomorphometry, treated horses had signifi-
cantly higher BS/TV (p = 0.02) and TbN (p = 0.02).
However, as outlined above, these results were not con-
firmed with microCT analyses, and overall, this accounts
for two out of 20 bone morphology parameters that
were significantly affected.
When evaluating changes from baseline to Day 60R
within CLO-treated horses, there was significantly
higher ES/BS (p = 0.03), as evaluated by static histomor-
phometry. However, the same effect was seen in the con-
trol horses after 60 days (ES/BS; p = 0.049). Comparing
CLO-treated horses to control horses within the Day
60R biopsy, CLO-treated horses had significantly less
ObS/BS (p = 0.04). Overall, this accounts for one of four
bone formation parameters, with no bone resorption pa-
rameters affected.
While few significant changes were identified in bone
morphology parameters following re-biopsy in the
control horses, there were areas identified within the re-
biopsy samples that clearly demonstrated reconstitution
and maturation of trabecular structure (Fig. 3). This in-
dicates that the Day 60R samples were composed at least
in part of non-native bone.
Discussion
This report describes the effect of a single administra-
tion, consistent with clinical dosages and administration,
of tiludronate or clodronate on bony cells, trabecular
bone morphology, bone remodeling, and bone regener-
ation in ten healthy, young horses. A previous study util-
izing a bone biopsy model attempted to elucidate
changes in bone morphology secondary to tiludronate
treatment in horses [19]. Unfortunately, the samples ob-
tained in that study were inadequate for evaluation of
bone morphology and remodeling; therefore, the current
study provides these missing data, and includes prelim-
inary data demonstrating no effect on bone regeneration
following re-biopsy of the original biopsy site. Addition-
ally, there have been no studies attempting to evaluate
the effect of clodronate, despite its prolific use in veter-
inary clinics. A barrier to the veterinary field is that
there is currently no data regarding whether tiludronate
or clodronate affects bone remodeling in the horse at
the recommended dosage and route of administration.
Therefore, the current study provides these preliminary
data indicating that there may be little to no effect on
bone remodeling at this timepoint. To our knowledge,
this is also the first study evaluating the cellular and
structural effect of tiludronate and clodronate in horses
of any age, as no published studies have evaluated these
changes in either skeletally mature or immature horses.
There were no significant effects of tiludronate or clo-
dronate on bony cells or bone structure and remodeling
parameters after 60 days in young horses, nor any
significant differences in treatment groups following
Fig. 3 MicroCT slices demonstrating morphological evidence of trabecular remodeling. Two dimensional microCT slices representing a 30 μm
thick section of an original biopsy (a) and re-biopsy (b) from the tuber coxae. Evidence of reconstitution and maturation of the trabecular structure is
evident in (b), indicating active bone remodeling following the original biopsy
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induction of an injury (re-biopsy of the original biopsy
site). Treatment success in the previous study [1] may
have been based on clodronate’s pain-minimizing prop-
erties, and not due to changes in bone remodeling. This
would explain the treatment success demonstrated in
that clinical trial [1], but support the lack of bony
changes shown in this study.
Overall, there were no effects on bone resorption or
bone remodeling kinetics, and only slight alterations in
bone formation parameters. Bisphosphonates, in general,
are widely known to affect bone remodeling kinetics,
specifically suppressing bone remodeling, as measured
by dynamic histomorphometry using fluorochrome la-
beling [29]. In the present study, there were bone
morphology changes found during static histomorpho-
metric evaluations that were not confirmed in microCT
results. Therefore, they were not considered in overall
conclusions, as microCT is a 3D measurement that ac-
counts for the entire biopsy, and has greater sensitivity
to bony measurements [24] when compared to histo-
morphometry. Additionally, when considering only a
couple of bone formation parameters were affected out
of over 20 parameters evaluated, including both directly
measured and calculated, the minor changes to bone for-
mation in the TIL-treated group is not considered a sig-
nificant conclusion.
A limitation of the current study is a low sample size
of 5 horses per group; therefore, it is possible that a
small effect of tiludronate or clodronate on bone remod-
eling and structure may not have been apparent, or that
the minor changes in bone formation parameters may
indicate true changes that would be more apparent using
a larger study population. However, it is well known that
bisphosphonates are powerful modifiers of the bone re-
modeling process, including in normal bone [30]. There-
fore, it was hypothesized that if there were a systemic
effect of tiludronate or clodronate administration in the
horse at the routine clinical dose administered, it would
have been detected in the current study. In addition, a
recent study evaluating the effect of the bone resorption
inhibitor cathepsin K, which does not fully prevent
osteoclastic resorption as bisphosphonates have been
shown to do [31], was performed with groups of 6
horses, with significant differences found [32]. Therefore,
we conclude that the lack of changes identified in the
current study, especially related to the re-biopsy results
and effects on a model of bone healing, are truly reflect-
ive of an overall lack of influence of these drugs on bone
remodeling kinetics in the horse. The authors are cur-
rently unsure of why a lack of effect was found in these
studies, and if horses have a different response to these
drugs than other species. Ongoing work is being con-
ducted to evaluate the effectiveness of these drugs to
bind to equine bone and the effect on the tissue and
bony cells in vitro. In addition, we are exploring whether
more modern bisphosphonates and/or other drugs used
to modify bone remodeling in other species have an ef-
fect in the horse.
It is possible that the time frame (60 days) evaluated in
this study was not appropriate to evaluate overall
changes in bone remodeling. As outlined in the
methods, this time frame was selected based on the only
published data regarding the effect of tiludronate and
clodronate on horses, which found significant clinical
improvements in horses diagnosed with navicular dis-
ease, distal tarsal osteoarthritis and osteoarthritis in the
axial skeleton after 60 days [1, 2, 5, 6, 21]. In addition, a
study evaluating bone remodeling in horses following
treatment with phenylbutazone, which, unlike tiludro-
nate, is not utilized as a treatment for diseases of bone
remodeling, found significant changes in MAR using
similar sample sizes after only 30 days [33]. Therefore, it
would be expected that normal bone apposition rates in
horses should be affected by tiludronate and clodronate
within the study timeframe. However, future studies in-
cluding additional time points post-treatment would be
required to confirm whether tiludronate or clodronate
has a significant impact on bone morphology. Similar
work would need to be done to fully characterize intra-
membranous and/or endochondral bone regeneration
and remodeling process following injury (i.e., re-biopsy)
at this location in order to determine an optimal time
point to evaluate potential effects of these drugs on bone
regeneration in the horse. As such, more recent data
evaluating effectiveness of tiludronate administration on
lameness associated with navicular disease as evaluated
by more objective force platform analyses found signifi-
cant improvements 120 and 200 days post treatment,
but not after 60 days [4]. Ideally, the studies presented
herein would be based on known timeframes regarding
bone remodeling kinetics in the horse as opposed to
strictly clinical outcomes data; however, the authors are
not aware such data exists.
Tiludronate and clodronate therapies are widely used
in the clinical setting to treat disorders involving abnor-
mal bone remodeling, including distal tarsal joint osteo-
arthritis [6], thoracic & lumbar vertebral arthritis [21],
and dorsal metacarpal disease [34]. Evaluations of tilu-
dronate on skeletally immature rats and baboons has
been reported [35, 36], and showed a reduction of tra-
becular bone resorption adjacent to growth plates and
increased bone density. Tiludronate and clodronate have
been previously evaluated for pathological bone changes
in horses aged 4 years and older [1, 2]; however, clini-
cians are administrating these drugs to horses that are
younger than 4 years of age, including off-label use for
treatment of dorsal metacarpal disease [34]. It is well
known that younger horses undergo more rapid bone
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remodeling than skeletally mature adults [37], and these
differences would be reflected in the chosen biopsy site,
so this study aimed to also evaluate the effect of tiludro-
nate and clodronate administration in young horses,
where negative impacts on normal bone remodeling
could result in detrimental clinical outcomes in young
equine athletes. As outlined above, we saw minimal, if
any, influence on bone remodeling or morphology in
this young population, and we would hypothesize to see
similar results in skeletally mature horses. However, due
to the smaller sample size for each age included the
study and the known effect of age on bone remodeling
parameters, there cannot be definitive conclusions based
on age. In addition to a larger number of subjects, a
smaller range of ages in subjects may have resulted in a
significant effect in other bone morphology parameters.
The iliac biopsy location utilized in the study was
chosen for multiple reasons. First, it has been shown
that bisphosphonates accumulate at the highest density
in the tuber coxae when compared to the 3rd metacarpal,
rib, and fourth tarsal bone in the horse [19]. Secondly, it is
an easily accessible location that allowed for a non-
terminal model. Thirdly, it has been shown that the tuber
coxae accurately predicts the effect of alendronate, an-
other form of bisphosphonate, on non-homogenous skel-
etal locations in the body (i.e., vertebral column) [38].
Bisphosphonates have been repeatedly shown to have sys-
temic effects on bone [39], especially trabecular bone [40],
so it can be reasonably argued that any changes that
would occur secondary to treatment with clodronate
would be identified in the selected biopsy location. The
anatomical location of the biopsy does have a few limita-
tions, including the lack of compressive forces upon it as
one would see in bony tissue of the distal limb; however,
the benefits of this biopsy method (e.g., ease of obtaining a
sample, large size, presence of both trabecular and cortical
bone) far outweigh the negatives [17]. However, care must
also be taken when evaluating the re-biopsy results, as this
model is novel and the exact timeline of intramembranous
and/or endochondral ossification at this location in the
horse has yet to be explored in detail. The morphology of
the samples (Fig. 3) indicates that at least part of the re-
biopsies contained non-native bone and therefore would
have been subjected to extensive remodeling during the
study timeframe. Given the relatively large biopsy size, this
study was able to utilize multiple study endpoints, includ-
ing both static and dynamic histomorphometry. The sec-
ond biopsy was prepared for un-decalcified histology in
order to preserve the fluorescent label, which required dif-
ferent preparation than the initial biopsy received. Al-
though preparation methods varied, methods of analyses
and outcome measures were identical for both preparation
methods of static histomorphometry sections [26]. In
addition, recent work has identified that outcomes of
evaluations of bony tissue and cells do not differ between
the two preparation techniques [25].
Conclusions
In conclusion, this study utilized several established
methods to evaluate bone morphology and remodeling
secondary to treatment with either tiludronate or clo-
dronate from a non-terminal bone biopsy method of the
equine tuber coxae. These data demonstrate that tiludro-
nate and clodronate do not have a substantial impact on
normal bone remodeling kinetics, morphology or bony
cells in young horses 60 days post-treatment. With the
lack of alteration of any expected bone remodeling pa-
rameters in these horses, the authors are unsure if clin-
ical improvement in lameness is due to effects on bone
remodeling or the analgesic effect of clodronate or other
effects secondary to bisphosphonate administration in
the horse. More studies are warranted to further explore
these negative findings, including the investigation of
clinically diseased horses.
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